Rucaparib cocrystal: Improved solubility and bioavailability over camsylate
- 30 November 2022
- journal article
- research article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 631, 122461
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Impact of the Dissolution Profile of the Cilostazol Cocrystal with Supersaturation on the Oral BioavailabilityCrystal Growth & Design, 2017
- Cocrystals of the antiandrogenic drug bicalutamide: screening, crystal structures, formation thermodynamics and lattice energiesCrystEngComm, 2016
- Correlating the melting point alteration with the supramolecular structure in aripiprazole drug cocrystalsCrystEngComm, 2016
- Physicochemical and mechanical properties of paracetamol cocrystal with 5-nitroisophthalic acidInternational Journal of Pharmaceutics, 2016
- Liquid chromatography–tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasmaJournal of Pharmaceutical and Biomedical Analysis, 2013
- Polymorphs, Salts, and Cocrystals: What’s in a Name?Crystal Growth & Design, 2012
- TheophyllinePharmaceuticals, 2010
- Continuously Substituted Solid Solutions of Organic Co-CrystalsCrystal Growth & Design, 2008
- Simultaneous kinetic-spectrophotometric determination of maltol and ethyl maltol in food samples by using chemometricsFood Chemistry, 2008
- The Salt−Cocrystal Continuum: The Influence of Crystal Structure on Ionization StateMolecular Pharmaceutics, 2007